The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
复制标题
DOI：
10.1016/j.ccr.2010.06.014
复制
发表时间：
2010-08-09
期刊：
影响因子：
50.3
通讯作者：
Fu YX
中科院分区：
文献类型：
--
作者：
Park S;Jiang Z;Mortenson ED;Deng L;Radkevich-Brown O;Yang X;Sattar H;Wang Y;Brown NK;Greene M;Liu Y;Tang J;Wang S;Fu YX
据报道，抗 HER2/neu 抗体疗法可通过中断致癌信号和/或诱导 FcR 介导的细胞毒性来介导肿瘤消退。在这里，我们证明这种疗法的肿瘤消退机制也需要适应性免疫反应。通过抗体治疗启动先天免疫和 T 细胞的激活是必要的。有趣的是，添加化疗药物虽然能够增强肿瘤负荷的减轻，但可能会消除抗体引发的免疫，导致对再次攻击的抵抗力下降或提前复发。通过选定的免疫疗法，增加先天性和适应性免疫细胞流入肿瘤微环境，进一步增强随后的抗体诱导的免疫，从而提高肿瘤根除率和对再次攻击的抵抗力。因此，本研究提出了抗HER2/neu抗体介导的肿瘤清除的模型和策略。
Anti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting oncogenic signals and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the mechanisms of tumor regression by this therapy also require the adaptive immune response. Activation of innate immunity and T cells, initiated by antibody treatment, was necessary. Intriguingly, the addition of chemotherapeutic drugs, while capable of enhancing the reduction of tumor burden, could abrogate antibody-initiated immunity leading to decreased resistance to re-challenge or earlier relapse. Increased influx of both innate and adaptive immune cells into the tumor microenvironment by a selected immunotherapy further enhanced subsequent antibody-induced immunity, leading to increased tumor eradication and resistance to re-challenge. Therefore, this study proposes a model and strategy for anti-HER2/neu antibody-mediated tumor clearance.
登录
查看更多内容
适应性免疫细胞缓和最初的先天反应。
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
10.3
作者：
Pegram, MD;Konecny, GE;Slamon, DJ
通讯作者：
Slamon, DJ
影响因子：
3.8
作者：
Lee, Sang Gyu;Jee, Young Geon;Seo, Jae Hong
通讯作者：
Seo, Jae Hong
DOI：
10.1126/science.1168988
发表时间：
2009-03-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Chen GY;Tang J;Zheng P;Liu Y
通讯作者：
Liu Y
影响因子：
20.3
作者：
Fan, ZS;Yu, P;Fu, YX
通讯作者：
Fu, YX